These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 19943706)
41. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282 [TBL] [Abstract][Full Text] [Related]
42. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Chen L; Su H; Shao H; Xu K; Liang S; Liu J Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077 [TBL] [Abstract][Full Text] [Related]
44. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700 [TBL] [Abstract][Full Text] [Related]
45. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167 [TBL] [Abstract][Full Text] [Related]
46. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Oseini AM; Roberts LR Expert Opin Ther Targets; 2009 Apr; 13(4):443-54. PubMed ID: 19335066 [TBL] [Abstract][Full Text] [Related]
47. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443 [TBL] [Abstract][Full Text] [Related]
49. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. Huynh H; Ong RW; Li PY; Lee SS; Yang S; Chong LW; Luu DA; Jong CT; Lam IW Anticancer Agents Med Chem; 2011 Jul; 11(6):560-75. PubMed ID: 21554207 [TBL] [Abstract][Full Text] [Related]
50. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497 [TBL] [Abstract][Full Text] [Related]
53. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma]. Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505 [No Abstract] [Full Text] [Related]
54. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma]. Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424 [TBL] [Abstract][Full Text] [Related]
55. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296 [TBL] [Abstract][Full Text] [Related]
57. Major achievements in hepatocellular carcinoma. Bruix J; Llovet JM Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618 [No Abstract] [Full Text] [Related]
58. Current management of hepatocellular carcinoma. Mendizabal M; Reddy KR Med Clin North Am; 2009 Jul; 93(4):885-900, viii. PubMed ID: 19577120 [TBL] [Abstract][Full Text] [Related]
59. Sorafenib: where do we go from here? Siegel AB; Olsen SK; Magun A; Brown RS Hepatology; 2010 Jul; 52(1):360-9. PubMed ID: 20578152 [TBL] [Abstract][Full Text] [Related]
60. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. Weintraub JL; Salem R J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]